Filing Flows › Krystal Biotech (KRYS) › Q3 2026 › vs Q2 2026
Krystal Biotech (KRYS) Q3 2026 vs Q2 2026 (quarter over quarter)
Krystal Biotech's revenue rose $8.1M (+7%) from $119M in Q2 2026 to $127M in Q3 2026. Operating margin 55.9% against 49.0% (+6.9 pts).
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 55.9% | 49.0% | +6.9 pts |
| Net margin | 49.5% | 45.9% | +3.6 pts |
| Free cash flow margin | 70.9% | 59.7% | +11.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $127M | $119M | $8.1M | +7% |
| Other income, net | $9.0M | $7.7M | $1.3M | +17% |
| Operating profit | $71.1M | $58.4M | $12.7M | +22% |
| Costs & expenses | $56.2M | $60.8M | −$4.6M | -8% |
| Pre-tax earnings | $80.1M | $66.1M | $14.1M | +21% |
| Research & development | $14.9M | $14.5M | $373K | +3% |
| SG&A | $33.7M | $39.9M | −$6.1M | -15% |
| Other operating costs | $7.6M | $6.4M | $1.1M | +17% |
| Net earnings | $63.1M | $54.8M | $8.3M | +15% |
| Income tax | $17.1M | $11.3M | $5.8M | +51% |
| Depreciation | $1.5M | $1.4M | $100K | +7% |
| Share-based compensation | $13.9M | $14.2M | −$217K | -2% |
| Working capital & other | $12.7M | $4.5M | $8.3M | +185% |
| Operating cash flow | $91.2M | $74.8M | $16.5M | +22% |
| Free cash flow (OCF − capex) | $90.3M | $71.2M | $19.0M | +27% |
| Capital expenditures | $996K | $3.6M | −$2.6M | -72% |
Questions
How much did Krystal Biotech's revenue grow quarter over quarter in Q3 2026?
Krystal Biotech's revenue rose $8.1M (+7%) from $119M in Q2 2026 to $127M in Q3 2026. Operating margin 55.9% against 49.0% (+6.9 pts).